Thermo Fisher buys Qiagen after all
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
Veracyte’s nasal lung cancer test results raise questions
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
Who will buy Qiagen?
The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.
Liquid biopsies: the future of cancer diagnosis?
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
Auris acquisition could prompt more mega VC rounds
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Oncocyte banks on a new kind of liquid biopsy
The Biotime-backed group believes it can use immune system gene expression levels to detect lung cancer earlier. But another trial will be necessary before the test can…
Illumina bets on Pacific, not nanopores
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.
Congenica aims to turn data into information
Sequencing data is all well and good, but what does it mean?
